HbA1c and coronary heart disease risk among diabetic patients
Wenhui Zhao1, Peter T Katzmarzyk, Ronald Horswell
1Corresponding author: Gang Hu, gang.hu@pbrc.edu.
Insights
Higher HbA1c levels in diabetic patients are linked to increased coronary heart disease (CHD) risk. This association was observed in both African American and white individuals, emphasizing the importance of glycemic control for cardiovascular health.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Public Health
Background:
- Clinical trials have not definitively established the link between glucose-lowering interventions and coronary heart disease (CHD) risk in diabetic patients.
- Type 2 diabetes is a significant risk factor for cardiovascular complications, including CHD.
Purpose of the Study:
- To prospectively investigate the association between glycated hemoglobin (HbA1c) levels and CHD risk in a large cohort of African American and white patients with type 2 diabetes.
- To examine the relationship of baseline and follow-up HbA1c levels with incident CHD events.
Main Methods:
- Prospective cohort study involving 17,510 African American and 12,592 white patients with type 2 diabetes.
- Data collected on HbA1c levels at baseline and during follow-up.
- Incident CHD cases were identified over a mean follow-up period of 6.0 years.
Main Results:
- A graded positive association was observed between higher HbA1c levels (both baseline and during follow-up) and increased CHD risk in both African American and white patients.
- The association between HbA1c and CHD risk was present across various demographic and clinical subgroups.
- A one percentage increase in HbA1c was associated with a greater increase in CHD risk among white patients compared to African American patients.
Conclusions:
- The study suggests a significant, graded positive association between HbA1c levels and CHD risk in low-income African American and white diabetic patients.
- Maintaining optimal glycemic control, as indicated by HbA1c levels, is crucial for reducing cardiovascular risk in patients with type 2 diabetes.
- These findings underscore the importance of ongoing monitoring and management of HbA1c to prevent CHD in diverse diabetic populations.
Objective:
Clinical trials to date have not provided definitive evidence regarding the effects of glucose lowering with coronary heart disease (CHD) risk among diabetic patients.
Research Design And Methods:
We prospectively investigated the association of HbA1c at baseline and during follow-up with CHD risk among 17,510 African American and 12,592 white patients with type 2 diabetes.
Results:
During a mean follow-up of 6.0 years, 7,258 incident CHD cases were identified. The multivariable-adjusted hazard ratios of CHD associated with different levels of HbA1c at baseline (<6.0 [reference group], 6.0-6.9, 7.0-7.9, 8.0-8.9, 9.0-9.9, 10.0-10.9, and ≥11.0%) were 1.00, 1.07 (95% CI 0.97-1.18), 1.16 (1.04-1.31), 1.15 (1.01-1.32), 1.26 (1.09-1.45), 1.27 (1.09-1.48), and 1.24 (1.10-1.40) (P trend = 0.002) for African Americans and 1.00, 1.04 (0.94-1.14), 1.15 (1.03-1.28), 1.29 (1.13-1.46), 1.41 (1.22-1.62), 1.34 (1.14-1.57), and 1.44 (1.26-1.65) (P trend <0.001) for white patients, respectively. The graded association of HbA1c during follow-up with CHD risk was observed among both African American and white diabetic patients (all P trend <0.001). Each one percentage increase of HbA1c was associated with a greater increase in CHD risk in white versus African American diabetic patients. When stratified by sex, age, smoking status, use of glucose-lowering agents, and income, this graded association of HbA1c with CHD was still present.
Conclusions:
The current study in a low-income population suggests a graded positive association between HbA1c at baseline and during follow-up with the risk of CHD among both African American and white diabetic patients with low socioeconomic status.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Diabetes Mellitus: Type 2 and Gestational
Hyperglycemia
Diabetic Retinopathy
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

